Cequent Pharmaceuticals, Inc is developing new
clinically compatible RNAi-based therapies.
05 May 2008
Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals’ Board of Directors. Click Here for Press Release
Click on the image below for Animation of Cequent's technology.
Home | Company | People | Research | Partners | Media | Contact
Legal Notice | Privacy Policy | Site Map
